These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 18590114)

  • 1. [Efficacy and safety of bivalos therapy for postmenopausal osteoporosis. Results of Russian multicenter trial].
    Rozhinskaia LIa; Arapova SD; Dzeranova LK; Molitvoslovova NN; Marova EI; Il'in AV; Benevolenskaia LI; Nikitinskaia OA; Korotkova TA; Toroptsova NV; Smirnov AV; Demin NV; Rodionova SS; Buklemeshev IuV; Shumskiĭ AA
    Ter Arkh; 2008; 80(5):47-52. PubMed ID: 18590114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial.
    Meunier PJ; Slosman DO; Delmas PD; Sebert JL; Brandi ML; Albanese C; Lorenc R; Pors-Nielsen S; De Vernejoul MC; Roces A; Reginster JY
    J Clin Endocrinol Metab; 2002 May; 87(5):2060-6. PubMed ID: 11994341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
    Meunier PJ; Roux C; Seeman E; Ortolani S; Badurski JE; Spector TD; Cannata J; Balogh A; Lemmel EM; Pors-Nielsen S; Rizzoli R; Genant HK; Reginster JY
    N Engl J Med; 2004 Jan; 350(5):459-68. PubMed ID: 14749454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of strontium ranelate in Asian women with postmenopausal osteoporosis.
    Hwang JS; Chen JF; Yang TS; Wu DJ; Tsai KS; Ho C; Wu CH; Su SL; Wang CJ; Tu ST
    Calcif Tissue Int; 2008 Nov; 83(5):308-14. PubMed ID: 18843436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strontium ranelate: a review of its use in the treatment of postmenopausal osteoporosis.
    Deeks ED; Dhillon S
    Drugs; 2010 Apr; 70(6):733-59. PubMed ID: 20394457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men.
    Kaufman JM; Audran M; Bianchi G; Braga V; Diaz-Curiel M; Francis RM; Goemaere S; Josse R; Palacios S; Ringe JD; Felsenberg D; Boonen S
    J Clin Endocrinol Metab; 2013 Feb; 98(2):592-601. PubMed ID: 23341486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years.
    Reginster JY; Bruyère O; Sawicki A; Roces-Varela A; Fardellone P; Roberts A; Devogelaer JP
    Bone; 2009 Dec; 45(6):1059-64. PubMed ID: 19679207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of strontium ranelate on serum leptin and bone turnover markers in women with established postmenopausal osteoporosis.
    Bayhan I; Dogan NU; Ozaksit G; Uygur D; Ugurlu N; Ugur M
    J Reprod Med; 2013; 58(7-8):319-23. PubMed ID: 23947082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
    Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ
    Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide.
    Anastasilakis AD; Polyzos SA; Avramidis A; Papatheodorou A; Terpos E
    Horm Metab Res; 2009 Jul; 41(7):559-62. PubMed ID: 19204890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of strontium ranelate for the mineralization of bone in postmenopausal women].
    Basurto L; Zárate A; Córdova N; Saucedo R; Galván R; Campos S; Hernández M
    Ginecol Obstet Mex; 2009 May; 77(5):227-30. PubMed ID: 19496517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strontium ranelate for osteoporosis?
    Drug Ther Bull; 2006 Apr; 44(4):29-32. PubMed ID: 16617933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Strontium ranelate].
    Masaki H; Miki T
    Clin Calcium; 2006 Jan; 16(1):137-44. PubMed ID: 16397364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial.
    Reginster JY; Deroisy R; Dougados M; Jupsin I; Colette J; Roux C
    Osteoporos Int; 2002 Dec; 13(12):925-31. PubMed ID: 12459934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
    Seeman E
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strontium ranelate in the prevention of osteoporotic fractures.
    Reginster JY; Malaise O; Neuprez A; Bruyere O
    Int J Clin Pract; 2007 Feb; 61(2):324-8. PubMed ID: 17263720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vitrum osteomag in prevention of osteoporosis in postmenopausal women: results of the comparative open multicenter trial].
    Benevolenskaia LI; Toroptsova NV; Nikitinskaia OA; Sharapova EP; Korotkova TA; Rozhinskaia LIa; Marova EI; Dzeranova LK; Molitvoslovova NN; Men'shikova LV; Grudinina OV; Lesniak OM; Evstigneeva LP; Smetnik VP; Shestakova IG; Kuznetsov SIu
    Ter Arkh; 2004; 76(11):88-93. PubMed ID: 15658548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Osteoporosis: from cost-effect characteristics to clinical efficacy and safety of strontium ranelate (bivalos)].
    Dydykina IS; Tsurko VV
    Ter Arkh; 2008; 80(5):85-91. PubMed ID: 18590124
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate.
    Middleton ET; Steel SA; Aye M; Doherty SM
    J Bone Miner Res; 2010 Mar; 25(3):455-62. PubMed ID: 20201000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.